An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)

NCT00796120 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

Sarcoma

Interventions

DRUG: Trabectedin
DRUG: Doxorubicin
DRUG: Ifosfamide

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]